PiB正电子发射断层显像/计算机断层显像用于转甲状腺素蛋白心脏淀粉样变性患者氯苯唑酸治疗监测的可行性
本文报告一例77岁野生型ATTR心脏淀粉样变性女性患者,接受氯苯唑酸治疗14个月后症状改善、NT-pro BNP降低;心脏MRI和PYP闪烁显像无显著变化且NaF摄取增加,而PiB PET/CT显示淀粉样沉积减少,提示PiB PET/CT在评估氯苯唑酸疗效方面可能优于NaF PET/CT。
要点
- 77岁女性野生型ATTR心脏淀粉样变性患者接受氯苯唑酸治疗14个月后症状改善、NT-pro BNP降低。
- 治疗后心脏MRI和PYP闪烁显像无显著变化,NaF PET/CT显示NaF蓄积增加。
- PiB PET/CT显示淀粉样沉积减少,提示其可能优于NaF PET/CT评估氯苯唑酸疗效。
核心结论
- PiB PET/CT显示淀粉样沉积减少,提示其在评估ATTR-CA患者氯苯唑酸疗效方面可能优于NaF PET/CT。
研究设计与样本
- 本文为一例77岁野生型ATTR心脏淀粉样变性女性患者的病例报告。
主要发现
- 患者表现为呼吸困难、心律失常和NT-pro BNP升高,初始心脏MRI、PYP闪烁显像、PiB PET/CT和NaF PET/CT均显示心脏异常。
- 氯苯唑酸治疗14个月后,患者症状改善且NT-pro BNP降低。
- 治疗后心脏MRI和PYP闪烁显像无显著变化,NaF PET/CT显示NaF蓄积增加,而PiB PET/CT显示淀粉样沉积减少。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We present a 77-year-old woman with wild-type ATTR cardiac amyloidosis (ATTR-CA) who presented with dyspnea, arrhythmia, and elevated NT-pro BNP. Initial imaging including cardiac MRI, PYP scintigraphy, PiB PET/CT and NaF PET/CT revealed cardiac abnormalities. Tafamidis treatment was initiated. After 14 months, symptomatic improvement and reduced NT-pro BNP were observed. Cardiac MRI and PYP scintigraphy showed no significant change and increased NaF accumulation, while PiB PET/CT showed decreased amyloid deposition, suggesting that it may be superior to NaF PET/CT in assessing the therapeutic effect of tafamidis in ATTR-CA.
引用
- Fujioka K, Norikane T, Takami Y, et al. Feasibility of PiB positron emission tomography/computed tomography for treatment monitoring with Tafamidis in a patient with transthyretin cardiac amyloidosis. J Nucl Cardiol. 2024. PMID: 38246259. doi:10.1016/j.nuclcard.2024.101816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。